Why is serum zinc unreliable, and what should I test instead?

How it works

Acute factors lowering serum zinc independent of body status: inflammation or infection (acute-phase shift to liver via metallothionein induction); recent meal (zinc redistribution to liver post-prandial); morning samples (diurnal variation, 30-50% lower mid-morning vs late afternoon); stress and cortisol; oestrogens (oral contraceptives lower); pregnancy (tissue redistribution). Acute factors raising serum zinc: zinc supplementation in preceding hours; haemolysis (red blood cells contain approximately 80% of blood zinc; haemolysed sample falsely elevates).

Effective dose

Long-term zinc above 25-40 mg/day causes copper deficiency via competitive absorption and induction of intestinal metallothionein (anaemia, leukopenia, neuropathy). Pair zinc with copper 1-2 mg/day if supplementing zinc above 25 mg/day long-term. Acute high-dose zinc (above 50 mg single dose) can cause GI upset and nausea. Zinc lozenges for cold-duration shortening use higher acute doses (50-80 mg/day for 3-7 days); short-term only, not chronic.

Forms compared

See the zinc form comparison entry (e9ecea5e) for full breakdown by application. Form selection for the lab-interpretation context follows the supplementation goal: glycinate is the typical default for general supplementation; citrate or picolinate as alternatives. Take with food to reduce GI upset; note that divalent metals compete (separate from iron, calcium, magnesium by 2 hours where possible).

Timing

RBC zinc reflects intracellular zinc over 8-12 weeks (RBC lifespan); more representative of tissue stores than serum zinc. Diurnal variation in serum zinc: 30-50% lower mid-morning vs late afternoon, complicating single-time-point interpretation. Recent meals shift zinc to liver post-prandial; fasting morning sample is the standard timing convention but does not eliminate the limitations.

Safety profile

Zinc-induced copper deficiency is a serious clinical syndrome (see zinc-copper interaction entries 206a1d13 and f39a9a43): copper-deficiency myelopathy, pancytopenia, sideroblastic anaemia. Long-term high-dose zinc lowers HDL and may affect lipid panel interpretation. Disclose zinc supplementation to clinicians interpreting copper, alkaline phosphatase, and lipid markers.

Special populations

Chronic kidney disease on dialysis: loses zinc through dialysate. Pregnancy and lactation: increased demand. Athletes with high sweat losses: relative deficiency possible. Long-term high-dose iron or calcium supplementation reduces zinc absorption competitively. UK adult zinc intake commonly meets requirements (RNI men 9.5 mg, women 7 mg per UK SACN); risk-group screening is more clinically useful than population-wide testing.

Interactions

Long-term high-dose iron or calcium supplementation reduces zinc absorption competitively; relevant when interpreting zinc status in users on chronic iron or calcium. Long-term high-dose zinc lowers HDL and affects lipid panel. Long-term high-dose zinc lowers serum copper and caeruloplasmin and may produce iron-non-responsive anaemia (caeruloplasmin is the iron-oxidising ferroxidase). PPI users may have lower baseline zinc absorption, which is relevant when interpreting normal-range serum zinc against a clinical picture suggesting deficiency.

Guideline positions

Alkaline phosphatase is a zinc-dependent metalloenzyme; persistently low ALP (below 50 U/L; some sources below 60) raises possibility of zinc deficiency. Caveats: ALP is also low in hypothyroidism, hypophosphatasia (rare genetic disorder), severe malnutrition, after gastric bypass surgery, on bisphosphonates, in pernicious anaemia occasionally, and as a benign finding in some healthy individuals. Persistently low ALP combined with consistent clinical picture (poor wound repair, recurrent infection) supports zinc deficiency. Copper:zinc ratio (serum copper / serum zinc): raised ratio (above 1.5) may indicate zinc deficiency relative to copper or excess copper; useful adjunct when both available. Hair zinc (HTMA): clinical interpretation has limitations and inter-lab standardisation issues. Urinary zinc/creatinine ratio: increased in marked supplementation but not routinely used.

Practical framework

Therapeutic trial approach: when serum zinc is normal but symptoms and risk factors suggest deficiency, trial 15-25 mg elemental zinc/day for 8 weeks (bisglycinate, picolinate, or citrate; avoid oxide). Response to supplementation in symptoms (taste, infection frequency, skin repair, energy) is clinically meaningful evidence supporting deficiency. Recheck after 8-12 weeks; if responding, continue with periodic break or reassessment. Pair with 1-2 mg copper if supplementing zinc long-term above 25 mg/day. This is a summary of published research, not personal health advice. Discuss any health or supplement decisions with a qualified healthcare professional, particularly during ongoing care, pregnancy, or with chronic conditions.

Common misconceptions

Claim: hair zinc (HTMA) is a definitive measure of body zinc status. Clinical interpretation has limitations and inter-lab standardisation issues; HTMA is not validated against tissue-level reference standards.

Claim: a low alkaline phosphatase always indicates zinc deficiency. Low ALP is also associated with hypothyroidism, hypophosphatasia, severe malnutrition, post-gastric-bypass status, bisphosphonate use, and as a benign finding; persistently low ALP plus consistent clinical picture is supportive but not specific.